2. Understanding the mechanism of action of adjuvants has been the key to success 3. The power of combination adjuvants 4. The progression of emulsion adjuvants 5. Capturing optimal synergy, the impact of AS01 6
The history of MF59((R)) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013;12(1):13-30. doi:10.1586/erv.12.140. Review.The history of MF59(?) adjuvant: a phoenix that arose from the ashes. O’Hagan Derek T,Ott Gary S,Nest Gary Van,Rappuoli Rino,Giudice ...
MF59 is an oil-in-water emulsion composed of squalene and the surfactants Tween 80 and Span85, firstly licensed as an adjuvant in a seasonal influenza vaccine for older adults in 1997 [62]. Even though the mechanism of action of this adjuvant is still not completely understood, MF59 was sho...
The effect of the proprietary adjuvant MF59 on the immunogenicity of a recombinant hepatitis B virus (HBV) vaccine, PreS2+SAg, was investigated in baboons. The magnitude and duration of the antibody response to hepatitis B surface antigen (anti-HBs) induced by the HBV/MF59 vaccine was compared...
LB-2Avian Influenza A/H7N9 Vaccine Mixed with MF59 Adjuvant at the Point-of-Use. A Randomized Clinical Trial of a Pandemic Threat ResponseLB-2Avian Influenza A/H7N9 Vaccine Mixed with MF59 Adjuvant at the Point-of-Use. A Randomized Clinical Trial of a Pandemic Threat Responsedoi:10.1093/ofid...
Adjuvants in licensed vaccines include alum, MF59, CpG 1018, AS01, AS02, AS03 and AS04, and several high-potency adju- vants are being evaluated in preclinical and clinical stud- ies. Adjuvants with immunostimulatory effects mimic damage-associated molecular patterns (DAMPs) or path- ogen-...
Using different adjuvants and viral vectors would be helpful to compare their efficacy in eliciting a stronger humoral response. Furthermore, these studies did not assess the neutralization activity, which is crucial to understand the Ab functional activity. It would have been beneficial to assess ...
The rapid development of COVID-19 vaccines and their deployment in less than a year is an unprecedented scientific, medical, and public health achievement. This rapid development leveraged knowledge from decades of HIV/AIDS research and advances. However, the search for an HIV vaccine that would ...
The adjuvants MF59 and LT-K63 were tested intramuscularly and intranasally with subunit HA. In naive mice, intranasal adjuvant effect was more apparent when included with the first than second immunization. In previously infected mice, intranasal adjuvants had little effect on serum antibodies and...
Historically, an ideal vaccine would be composed of an antigen or multiple antigens, adjuvant(s), and a delivery platform that can specifically be effective against the target infection, safe to a broad range of populations, and capable of inducing long-term immunity. This review outlines SARS-...